An 11C-labeled selective adenosine A2A antagonist, (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-[11C]-methylxanthine ([11C]KF17837), was prepared by reaction of (E)-8-(3,4-dimethoxystyryl)-1,3-dipropylxanthine and [11C]methyl iodide with decay-corrected radiochemical yield of 19-50%, radiochemical pur
Synthesis and preliminary evaluation of [11C]KF15372, a selective adenosine A1 antagonist
β Scribed by Kiichi Ishiwata; Riko Furuta; Jun-Ichi Shimada; Shin-Ichi Ishii; Kazutoyo Endo; Fumio Suzuki; Michio Senda
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 405 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0969-8043
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract We demonstrated the synthesis of carbonβ11 labeled 17β__Ξ±__βhydroxyβ11β__Ξ²__β/4β/[methyl]β[1βmethylethyl]βaminophenyl/β17__Ξ±__β[propβ1βynyl]estaβ4β9βdieneβ3βone (RU40555), a selective glucocorticoid receptor (GR) antagonist, and examined the __in vivo__ profile of [^11^C]RU40555. [^11^
## Abstract For Abstract see ChemInform Abstract in Full Text.
Movement disorders such as Parkinson's disease and Huntington's disease are serious life-limiting and debilitating movement disorders. Their onset typically occurs from mid-life to late in life, and effective diagnostic techniques for detecting and following the disease course are lacking. Our goal